Read by QxMD icon Read

Sarcoma brennan

Ashley E Russo, Brian R Untch, Mark G Kris, Joanne F Chou, Marinela Capanu, Daniel G Coit, Jamie E Chaft, Michael I D'Angelica, Murray F Brennan, Vivian E Strong
OBJECTIVE: To determine if there are differences in overall survival (OS) or event-free survival (EFS) in patients with and without concomitant extra-adrenal metastases undergoing adrenal metastasectomy. BACKGROUND: There is growing interest in the use of local therapies in patients with oligometastatic disease. Previously published series have indicated that long-term survival is possible with resection. Adrenalectomy has been used to treat adrenal metastases in select patients...
March 23, 2018: Annals of Surgery
Daniel Orbach, Véronique Mosseri, Daniel Pissaloux, Gaelle Pierron, Bernadette Brennan, Andrea Ferrari, Frederic Chibon, Gianni Bisogno, Gian Luca De Salvo, Camille Chakiba, Nadège Corradini, Véronique Minard-Colin, Anna Kelsey, Dominique Ranchère-Vince
A genomic index (GI) tool using array comparative genomic hybridization (aCGH) on tumor cells has emerged as independent prognostic factor associated with the risk of metastatic relapse in synovial sarcoma (SS). The aim was to assess GI in pediatric patients with SS, to determine its value as a prognostic factor. All pediatric/adolescent/young adults' (<25 years) with localized SS prospectively included in the European EpSSG-NRSTS05 protocol with a contributive aCGH were selected. Definition of GI was A2 /C, where A is the total number of alterations (segmental gains and losses) and C is the number of involved chromosomes on aCGH results...
April 2018: Cancer Medicine
Bernadette Brennan, Ilaria Zanetti, Daniel Orbach, Soledad Gallego, Nadine Francotte, Max Van Noesel, Anna Kelsey, Michela Casanova, Gian Luca De Salvo, Gianni Bisogno, Andrea Ferrari
BACKGROUND: As alveolar soft part sarcomas (ASPS) are rare with no prospective series within pediatric sarcoma trials, the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) examined the clinical data and outcomes of ASPS enrolled in a multinational study of nonrhabdomyosarcoma soft tissue sarcomas (NRSTS). PATIENTS AND METHODS: Twenty-two patients with ASPS were enrolled into the EpSSG NRSTS 2005 study. After surgical resection, subsequent treatment depended on the stratification of patients for completeness of resection and Intergroup Rhabdomyosarcoma Study (IRS) stage, size, and French Federation of Cancer Centres Sarcoma Group (FNCLCC) grade...
April 2018: Pediatric Blood & Cancer
Neel P Chudgar, Murray F Brennan, Kay See Tan, Rodrigo R Munhoz, Sandra P D'Angelo, Manjit S Bains, James Huang, Bernard J Park, Prasad S Adusumilli, William D Tap, David R Jones
BACKGROUND: Because recurrence is high after pulmonary metastasectomy (PM) for soft tissue sarcoma (STS), repeat PM is commonly performed. Our objective was to define the selection criteria for repeat PM among patients experiencing recurrence and to identify factors associated with survival. METHODS: We reviewed a prospectively maintained database of 539 patients undergoing PM for STS. Characteristics of the primary tumor, metastatic disease, treatment, and recurrence were examined...
December 2017: Annals of Thoracic Surgery
Teresa Santiago, Michael R Clay, Elizabeth Azzato, Scott Newman, Israel Fernandez-Pineda, Kim E Nichols, Jinghui Zhang, James R Downing, Andrew Davidoff, Rachel C Brennan, David W Ellison
Clear cell sarcoma of kidney (CCSK) is a rare renal malignancy, previously unreported in horseshoe kidney (HSK). B-cell lymphoma 6 corepressor (BCOR) gene internal tandem duplication (ITD) was identified as a recurrent somatic alteration in approximately 85% of CCSKs. This and the YWHAE-NUTM2B/E fusion, the second most common recurrent molecular alteration in CCSK (10%), are considered to be mutually exclusive. However, there is a subset of CCSKs that do not harbor either the BCOR-ITD or YWHAE-NUTM2 translocation and lack known molecular alterations...
November 2017: Pediatric Blood & Cancer
Neel P Chudgar, Murray F Brennan, Rodrigo R Munhoz, Peter R Bucciarelli, Kay See Tan, Sandra P D'Angelo, Manjit S Bains, Matthew Bott, James Huang, Bernard J Park, Valerie W Rusch, Prasad S Adusumilli, William D Tap, Samuel Singer, David R Jones
OBJECTIVE: Soft-tissue sarcoma is a heterogeneous disease that frequently includes the development of pulmonary metastases. The purpose of this study is to determine factors associated with improved survival among patients with soft-tissue sarcoma to help guide selection for pulmonary metastasectomy. METHODS: We reviewed a prospectively maintained database and identified 803 patients who underwent pulmonary metastasectomy for metastatic soft-tissue sarcoma between September 1991 and June 2014; of these, 539 patients undergoing 760 therapeutic-intent pulmonary metastasectomies were included...
July 2017: Journal of Thoracic and Cardiovascular Surgery
Andrea Ferrari, Yueh-Yun Chi, Gian Luca De Salvo, Daniel Orbach, Bernadette Brennan, R Lor Randall, M Beth McCarville, Jennifer O Black, Rita Alaggio, Douglas S Hawkins, Gianni Bisogno, Sheri L Spunt
BACKGROUND: Multimodal risk-adapted treatment is used in paediatric protocols for synovial sarcoma (SS). Retrospective analyses suggest that low-risk SS patients can be safely treated with surgery alone, but no prospective studies have confirmed the safety of this approach. This analysis pooled data from the two prospective clinical trials to assess outcomes in SS patients treated with a surgery-only approach and to identify predictors of treatment failure. METHODS: Patients with localised SS enrolled on the European paediatric Soft tissue sarcoma Study Group (EpSSG) NRSTS2005 and on the Children Oncology Group (COG) ARST0332 trials, treated with surgery alone were eligible for this analysis...
June 2017: European Journal of Cancer
Ben Tudor-Green, Felipe Paiva Fonseca, Ricardo S Gomez, Peter A Brennan
Head and neck hard tissue sarcomas form a rare group of mesenchymal-derived tumours that comprise less than 1% of all head and neck neoplasms. Hard tissue sarcomas account for 20% of head and neck sarcomas and they form a heterogeneous group with a diverse origin. Unlike head and neck soft-tissue sarcomas, they have lower recurrence and mortality rates. In this study, we review the current management of head and neck hard tissue sarcomas.
October 2017: Journal of Oral Pathology & Medicine
Ben Tudor-Green, Ricardo Gomez, Peter A Brennan
Head and neck soft tissue sarcomas are a group of rare heterogeneous tumours arising from embryonic mesoderm. They comprise <1% of all head and neck malignancies and 5-15% of all sarcomas with most head and neck sarcomas arising from soft tissues. Although rare, they are associated with both high recurrence and mortality rates. We review the current management of head and neck soft tissue sarcomas.
October 2017: Journal of Oral Pathology & Medicine
Bernadette Brennan, Charles Stiller, Robert Grimer, Nicola Dennis, John Broggio, Matthew Francis
BACKGROUND: The role of age as a prognostic factor has been examined in single institutional studies and in larger data sets from the SEER database, showing a survival advantage for younger versus adult patients with synovial sarcoma (SS). To further assess the role of age, socioeconomic status and other prognostic factors on outcome for SS, we analysed a contemporary all-age population-based cohort of patients with SS registered in England. METHODS: The data on 1318 synovial sarcomas diagnosed in England between 1985 and 2009 were retrospectively analysed for incidence, and the effect of age, patient characteristics and deprivation on outcome using both univariate and multivariate analysis...
2016: Clinical Sarcoma Research
Neyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, Mark Bernstein, Gordana Jovic, Mark D Krailo, Jane M Hook, Carola Arndt, Henk van den Berg, Bernadette Brennan, Bénédicte Brichard, Ken L B Brown, Trude Butterfass-Bahloul, Gabriele Calaminus, Heike E Daldrup-Link, Mikael Eriksson, Mark C Gebhardt, Hans Gelderblom, Joachim Gerss, Robert Goldsby, Allen Goorin, Richard Gorlick, Holcombe E Grier, Juliet P Hale, Kirsten Sundby Hall, Jendrik Hardes, Douglas S Hawkins, Knut Helmke, Pancras C W Hogendoorn, Michael S Isakoff, Katherine A Janeway, Heribert Jürgens, Leo Kager, Thomas Kühne, Ching C Lau, Patrick J Leavey, Stephen L Lessnick, Leo Mascarenhas, Paul A Meyers, Hubert Mottl, Michaela Nathrath, Zsuzsanna Papai, R Lor Randall, Peter Reichardt, Marleen Renard, Akmal Ahmed Safwat, Cindy L Schwartz, Michael C G Stevens, Sandra J Strauss, Lisa Teot, Mathias Werner, Matthew R Sydes, Jeremy S Whelan
BACKGROUND: We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. METHODS: EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation...
October 2016: Lancet Oncology
Leo Kager, Jeremy Whelan, Uta Dirksen, Bass Hassan, Jakob Anninga, Lindsey Bennister, Judith V M G Bovée, Bernadette Brennan, Javier M Broto, Laurence Brugières, Anne-Marie Cleton-Jansen, Christopher Copland, Aurélie Dutour, Franca Fagioli, Stefano Ferrari, Marta Fiocco, Emmy Fleuren, Nathalie Gaspar, Hans Gelderblom, Craig Gerrand, Joachim Gerß, Ornella Gonzato, Winette van der Graaf, Stefanie Hecker-Nolting, David Herrero-Martín, Stephanie Klco-Brosius, Heinrich Kovar, Ruth Ladenstein, Carlo Lancia, Marie-Cecile LeDeley, Martin G McCabe, Markus Metzler, Ola Myklebost, Michaela Nathrath, Piero Picci, Jenny Potratz, Françoise Redini, Günther H S Richter, Denise Reinke, Piotr Rutkowski, Katia Scotlandi, Sandra Strauss, David Thomas, Oscar M Tirado, Franck Tirode, Gilles Vassal, Stefan S Bielack
This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations...
2016: Clinical Sarcoma Research
Stéphanie Foulon, Bernadette Brennan, Nathalie Gaspar, Uta Dirksen, Lee Jeys, Anna Cassoni, Line Claude, Beatrice Seddon, Perrine Marec-Berard, Jeremy Whelan, Michael Paulussen, Arne Streitbuerger, Odile Oberlin, Heribert Juergens, Robert Grimer, Marie-Cécile Le Deley
BACKGROUND: The role of postoperative radiotherapy (PORT) in Ewing sarcoma (ES) is unclear. We assessed the impact of PORT on local control in patients with localised ES and good histological response to chemotherapy (<10% cells). PATIENTS AND METHODS: All randomised patients in the EE99-R1 trial (comparing two consolidation chemotherapy regimens) undergoing surgery after induction chemotherapy were included. Local relapse (LR) cumulative incidence was estimated using a competing risk approach...
July 2016: European Journal of Cancer
Craig Gerrand, Nick Athanasou, Bernadette Brennan, Robert Grimer, Ian Judson, Bruce Morland, David Peake, Beatrice Seddon, Jeremy Whelan
This document is an update of the British Sarcoma Group guidelines published in 2010. The aim is to provide a reference standard for the clinical care of patients in the UK with bone sarcomas. Recent recommendations by the European Society of Medical Oncology, The National Comprehensive Cancer Network and The National Institute for Health and Care Excellence have been incorporated, and the literature since 2010 reviewed. The standards represent a consensus amongst British Sarcoma Group members in 2015. It is acknowledged that these guidelines will need further updates as care evolves...
2016: Clinical Sarcoma Research
Bernadette Brennan, Gian Luca De Salvo, Daniel Orbach, Angela De Paoli, Anna Kelsey, Peter Mudry, Nadine Francotte, Max Van Noesel, Gianni Bisogno, Michela Casanova, Andrea Ferrari
BACKGROUND: Extracranial malignant rhabdoid tumours (MRT) are rare lethal childhood cancers that often occur in infants and have a characteristic genetic mutation in the SMARCB1 gene. The European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) conducted a multinational prospective study of registered cases of extracranial MRT to test an intensive multimodal approach of treatment for children with newly diagnosed extracranial MRT. METHODS: Between December 2005 and June 2014, we prospectively registered 100 patients from 12 countries with a diagnosis of MRT tumour at an extracranial site on the EpSSG Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study (NRSTS 2005)...
June 2016: European Journal of Cancer
Pierre Avril, Louis-Romée Le Nail, Meadhbh Á Brennan, Philippe Rosset, Gonzague De Pinieux, Pierre Layrolle, Dominique Heymann, Pierre Perrot, Valérie Trichet
Conventional therapy of primary bone tumors includes surgical excision with wide resection, which leads to physical and aesthetic defects. For reconstruction of bone and joints, allografts can be supplemented with mesenchymal stem cells (MSCs). Similarly, adipose tissue transfer (ATT) is supplemented with adipose-derived stem cells (ADSCs) to improve the efficient grafting in the correction of soft tissue defects. MSC-like cells may also be used in tumor-targeted cell therapy. However, MSC may have adverse effects on sarcoma development...
March 2016: Journal of Bone Oncology
Daniel Orbach, Bernadette Brennan, Angela De Paoli, Soledad Gallego, Peter Mudry, Nadine Francotte, Max van Noesel, Anna Kelsey, Rita Alaggio, Dominique Ranchère, Gian Luca De Salvo, Michela Casanova, Christophe Bergeron, Johannes H M Merks, Meriel Jenney, Michael C G Stevens, Gianni Bisogno, Andrea Ferrari
BACKGROUND: Infantile fibrosarcoma (IFS) is a very rare disease occurring in young infants characterised by a high local aggressiveness but overall with a favourable survival. To try to reduce the total burden of therapy, the European pediatric Soft tissue sarcoma Study Group has developed conservative therapeutic recommendations according to initial resectability. MATERIAL AND METHODS: Between 2005 and 2012, children with localised IFS were prospectively registered...
April 2016: European Journal of Cancer
Ann Y Lee, Narasimhan P Agaram, Li-Xuan Qin, Deborah Kuk, Christina Curtin, Murray F Brennan, Samuel Singer
BACKGROUND: Myxofibrosarcoma and undifferentiated pleomorphic sarcoma (UPS) are aggressive, genetically complex sarcomas. The minimum myxoid component used as a criterion for myxofibrosarcoma varies widely, so we determined the optimal myxoid component cutpoints for stratifying outcomes of UPS and myxofibrosarcoma. We also analyzed clinicopathologic factors associated with outcome. METHODS: Review of a prospective, single-institution database identified 197 patients with primary, high-grade extremity/truncal myxofibrosarcoma or UPS resected during 1992-2013...
March 2016: Annals of Surgical Oncology
Jason A Davis, Brennan Roper, John W Munz, Timothy S Achor, Matthew Galpin, Andrew M Choo, Joshua L Gary
BACKGROUND: Controversy regarding heterotopic ossification (HO) prophylaxis exists after Kocher-Langenbeck for treatment of acetabular fracture. Prophylaxis options include antiinflammatory oral medications, single-dose radiation therapy, and débridement of gluteus minimus muscle. Prior literature has suggested single-dose radiation therapy as the best prophylaxis to prevent HO formation. However, recent reports have emerged of radiation-induced sarcoma after radiotherapy for HO prophylaxis, which has led many surgeons to reconsider the risks and benefits of single-dose radiation therapy...
June 2016: Clinical Orthopaedics and related Research
Nathalie Gaspar, Douglas S Hawkins, Uta Dirksen, Ian J Lewis, Stefano Ferrari, Marie-Cecile Le Deley, Heinrich Kovar, Robert Grimer, Jeremy Whelan, Line Claude, Olivier Delattre, Michael Paulussen, Piero Picci, Kirsten Sundby Hall, Hendrik van den Berg, Ruth Ladenstein, Jean Michon, Lars Hjorth, Ian Judson, Roberto Luksch, Mark L Bernstein, Perrine Marec-Bérard, Bernadette Brennan, Alan W Craft, Richard B Womer, Heribert Juergens, Odile Oberlin
Ewing sarcoma (ES) is an aggressive sarcoma of bone and soft tissue occurring at any age with a peak incidence in adolescents and young adults. The treatment of ES relies on a multidisciplinary approach, coupling risk-adapted intensive neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between pediatric and medical oncologists...
September 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"